Elanco Animal Health Incorporated $ELAN Shares Bought by AQR Capital Management LLC

AQR Capital Management LLC boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 116.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 524,507 shares of the company’s stock after buying an additional 282,081 shares during the quarter. AQR Capital Management LLC owned 0.11% of Elanco Animal Health worth $5,332,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Allworth Financial LP lifted its holdings in Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after buying an additional 2,090 shares in the last quarter. CoreCap Advisors LLC acquired a new stake in Elanco Animal Health during the 4th quarter worth approximately $29,000. Parallel Advisors LLC lifted its holdings in Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after buying an additional 1,852 shares in the last quarter. NBC Securities Inc. acquired a new stake in Elanco Animal Health during the 1st quarter worth approximately $40,000. Finally, Versant Capital Management Inc lifted its holdings in Elanco Animal Health by 65.9% during the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock worth $46,000 after buying an additional 1,740 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Down 1.4%

Shares of Elanco Animal Health stock opened at $18.52 on Friday. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $19.08. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The company has a market capitalization of $9.20 billion, a P/E ratio of 21.53, a PEG ratio of 3.49 and a beta of 1.62. The company’s fifty day moving average is $16.37 and its two-hundred day moving average is $13.18.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period last year, the firm posted $0.30 EPS. Elanco Animal Health’s revenue for the quarter was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ELAN. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. UBS Group increased their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Piper Sandler increased their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, August 11th. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 20th. Finally, William Blair raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research report on Thursday, June 26th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.